RU2015126651A - Способы скрининга - Google Patents

Способы скрининга Download PDF

Info

Publication number
RU2015126651A
RU2015126651A RU2015126651A RU2015126651A RU2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A
Authority
RU
Russia
Prior art keywords
nodular
peptide
mass spectrum
peptides
light
Prior art date
Application number
RU2015126651A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс ОЛСОН
Кристофер Мехлин
Марк СТРОУД
Джулиан САЙМОН
Колин КОРРЕНТИ
Патрик ПАДДИСОН
Роналд СТРОНГ
Дамон МАЙ
Original Assignee
Фред Хатчинсон Кэнсер Рисёрч Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фред Хатчинсон Кэнсер Рисёрч Сентер filed Critical Фред Хатчинсон Кэнсер Рисёрч Сентер
Publication of RU2015126651A publication Critical patent/RU2015126651A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
RU2015126651A 2012-12-10 2013-12-10 Способы скрининга RU2015126651A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261735516P 2012-12-10 2012-12-10
US61/735,516 2012-12-10
US201361794685P 2013-03-15 2013-03-15
US61/794,685 2013-03-15
PCT/US2013/074218 WO2014093406A1 (en) 2012-12-10 2013-12-10 Methods for screening

Publications (1)

Publication Number Publication Date
RU2015126651A true RU2015126651A (ru) 2017-01-16

Family

ID=49883268

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015126651A RU2015126651A (ru) 2012-12-10 2013-12-10 Способы скрининга
RU2015126650A RU2015126650A (ru) 2012-12-10 2013-12-10 Партнеры липокалина по слиянию

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015126650A RU2015126650A (ru) 2012-12-10 2013-12-10 Партнеры липокалина по слиянию

Country Status (11)

Country Link
US (4) US10156559B2 (OSRAM)
EP (2) EP2928913A1 (OSRAM)
JP (2) JP2016505826A (OSRAM)
CN (2) CN105189540A (OSRAM)
AU (2) AU2013359429A1 (OSRAM)
BR (2) BR112015013525A2 (OSRAM)
CA (2) CA2913029A1 (OSRAM)
IL (2) IL239261A0 (OSRAM)
RU (2) RU2015126651A (OSRAM)
SG (2) SG11201504600UA (OSRAM)
WO (2) WO2014093406A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795983C2 (ru) * 2018-04-12 2023-05-16 Етх Цюрих Мнс-дисплей пептидов млекопитающего как инструмент для выбора антигенной детерминанты при создании вакцин

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR101576904B1 (ko) 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CA2980838A1 (en) * 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CN107847554A (zh) * 2015-06-26 2018-03-27 弗莱德哈钦森癌症研究中心 治疗性肽及其使用方法
JP2018521994A (ja) * 2015-06-26 2018-08-09 フレッド ハッチンソン キャンサー リサーチ センター 治療用ペプチドおよびそれらの使用方法
JP6966424B2 (ja) * 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
PT3362470T (pt) * 2015-10-13 2021-12-10 Hope City Recetores de antigénios quiméricos que contêm um domínio de clorotoxina
EP3373952A4 (en) * 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
CN105348392B (zh) * 2015-11-18 2019-08-02 北京华金瑞清生物医药技术有限公司 一种Nav1.7抑制剂及其改造方法
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER
AU2017250359B2 (en) 2016-04-15 2022-06-16 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2018039283A1 (en) * 2016-08-22 2018-03-01 Fred Hutchinson Cancer Research Center Peptides and methods of use thereof
EP4529966A3 (en) 2016-08-29 2025-06-18 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
CN106699866A (zh) * 2016-12-13 2017-05-24 山西农业大学 一种鸡细胞外脂肪酸结合蛋白、原核表达及其纯化方法
WO2018136614A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
CN110475565A (zh) * 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
WO2018232122A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
WO2019178573A1 (en) * 2018-03-16 2019-09-19 Blaze Bioscience, Inc. Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
WO2021126341A1 (en) * 2019-12-19 2021-06-24 Blaze Bioscience, Inc. Methods of treating vascular lesions and malformations
CN115329965B (zh) * 2022-08-16 2025-08-01 北京有竹居网络技术有限公司 数据处理方法和电子设备
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
AU617652B2 (en) 1986-09-19 1991-12-05 Scripps Clinic And Research Foundation Monoclonal paratopic molecule directed to human ganglioside gd2
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
ATE275197T1 (de) 1991-09-20 2004-09-15 Amgen Inc Glial neurotrophe faktor
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
WO1993023075A1 (en) 1992-05-14 1993-11-25 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
RU2148401C1 (ru) 1993-01-13 2000-05-10 Канзер Рисерч Кампейн Технолоджи, Лтд. Фармацевтическая композиция с антиопухолевой активностью и способ ее получения
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
AU2889097A (en) * 1996-05-10 1997-12-05 Novartis Ag Identification of members of combinatorial libraries by mass spectrometry
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
EP1055684A4 (en) 1997-12-05 2002-12-04 Kyogo Itoh TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES
GB9809776D0 (en) * 1998-05-07 1998-07-08 Nycomed Imaging As Method
WO2000009502A1 (en) 1998-08-12 2000-02-24 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
AU755334C (en) * 1998-08-25 2004-02-26 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6629040B1 (en) * 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2384429A1 (en) 1999-09-14 2001-03-22 Michael K. Bahr Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
AU2002220265A1 (en) 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
WO2002069896A2 (en) 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20030021810A1 (en) 2001-06-26 2003-01-30 Sontheimer Harald W. Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
EP1480665A2 (en) 2002-02-04 2004-12-01 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
MXPA04011871A (es) 2002-05-31 2005-07-26 Transmolecular Inc Quimioterapia en combinacion con clorotoxina.
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7563600B2 (en) * 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
CN1791671A (zh) * 2003-03-21 2006-06-21 先灵公司 靶配体的筛选方法
US20050059038A1 (en) * 2003-03-21 2005-03-17 Adams Steven P. Method of screening for target ligands
WO2005099774A2 (en) 2004-04-06 2005-10-27 Transmolecular, Inc. Diagnosis and treatment of myeloid and lymphoid cell cancers
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
US20070275902A1 (en) 2003-11-26 2007-11-29 Transmolecular, Inc. Treatment of Phosphatidylinositol Phospholipid Disorders
EP1544296B8 (fr) * 2003-12-18 2009-08-05 Biomethodes Procédé de mutagenèse dirigée massive
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
JP2007536260A (ja) 2004-05-06 2007-12-13 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 虚血性および腎毒性障害の軽減および改善用ｎｇａｌ
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
US20090209615A1 (en) * 2004-09-27 2009-08-20 Stuart Lipton Inhibitors of matrix metalloproteinases to treat neurological disorders
GB0422901D0 (en) * 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) * 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
EP1877428B1 (en) 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
KR101285904B1 (ko) 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 ｔＲＮＡ 조성물 및 이의 용도
US20070237714A1 (en) 2006-03-31 2007-10-11 Alvarez Vernon L Diagnosis and treatment of tumors
WO2007137163A2 (en) 2006-05-19 2007-11-29 Georgia Tech Research Corporation Abc transporter ligand
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2009021136A1 (en) 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
US20110283260A1 (en) 2007-08-31 2011-11-17 Iosemantics, Llc Quality assurance tools for use with source code and a semantic model
CN101918041A (zh) 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
JP5746861B2 (ja) 2007-10-19 2015-07-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 哺乳動物のｎｇａｌに結合する抗体及びその使用
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
PL2215481T5 (pl) 2007-11-15 2017-10-31 Bioporto Diagnostics As Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera
CA2749108C (en) 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8093060B2 (en) 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
EP3673922A1 (en) 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
CA2718854A1 (en) 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition of angiogenesis
GB0807831D0 (en) 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
JP2009300110A (ja) 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
JP5711118B2 (ja) * 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
US20100098637A1 (en) 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
JP2010085108A (ja) 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
US20100331650A1 (en) * 2009-06-25 2010-12-30 Roche Diagnostics Operations, Inc. Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof
US10191060B2 (en) 2009-11-09 2019-01-29 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
HRP20171291T1 (hr) 2010-02-04 2017-10-20 Morphotek, Inc. Polipeptidi i konjugati klorotoksina i njihove uporabe
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
DK2606061T3 (da) * 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
EP3604549A1 (en) * 2010-11-08 2020-02-05 The Board of Trustees of the Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US10436803B2 (en) * 2010-12-28 2019-10-08 Quest Diagnostics Investments Incorporated Quantitation of insulin by tandem mass spectrometry of insulin B chain
MX360438B (es) * 2011-09-07 2018-11-01 X Chem Inc Metodos para etiquetar bibliotecas codificadas por adn.
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795983C2 (ru) * 2018-04-12 2023-05-16 Етх Цюрих Мнс-дисплей пептидов млекопитающего как инструмент для выбора антигенной детерминанты при создании вакцин

Also Published As

Publication number Publication date
SG11201504602VA (en) 2015-07-30
CA2913127A1 (en) 2014-06-19
US20140179560A1 (en) 2014-06-26
BR112015013525A2 (pt) 2017-11-14
AU2013359426A2 (en) 2015-11-05
EP2928913A1 (en) 2015-10-14
US20190101528A1 (en) 2019-04-04
US10156559B2 (en) 2018-12-18
IL239261A0 (en) 2015-07-30
WO2014093403A1 (en) 2014-06-19
US20150316536A1 (en) 2015-11-05
JP2016505251A (ja) 2016-02-25
AU2013359429A2 (en) 2015-11-12
CN105008393A (zh) 2015-10-28
AU2013359429A1 (en) 2015-07-09
EP2928914A1 (en) 2015-10-14
IL239262A0 (en) 2015-07-30
BR112015013515A2 (pt) 2017-11-14
JP2016505826A (ja) 2016-02-25
US20150322123A1 (en) 2015-11-12
WO2014093406A1 (en) 2014-06-19
CA2913029A1 (en) 2014-06-19
SG11201504600UA (en) 2015-07-30
CN105189540A (zh) 2015-12-23
AU2013359426A1 (en) 2015-07-09
RU2015126650A (ru) 2017-01-12

Similar Documents

Publication Publication Date Title
RU2015126651A (ru) Способы скрининга
AU2021250887B2 (en) Immunogenic mutant peptide screening platform
Huttunen et al. A selective and slowly reversible inhibitor of l-type amino acid transporter 1 (LAT1) potentiates antiproliferative drug efficacy in cancer cells
Chen et al. Identification of MHC peptides using mass spectrometry for neoantigen discovery and cancer vaccine development
Lewandrowski et al. Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes
US20090092553A1 (en) Monocarboxylate transporters expressed in cancer cells
Xie et al. Use of glioma to assess the distribution patterns of perfluoroalkyl and polyfluoroalkyl substances in human brain
Schneider et al. Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities
Xiong et al. Peptide-based imaging agents targeting phosphatidylserine for the detection of apoptosis
ES2987813T3 (es) Métodos para identificar péptidos tumorales asociados al HLA
Zhang et al. Double-stranded DNA enhances platelet activation, thrombosis, and myocardial injury via cyclic GMP-AMP synthase
Marucci et al. Anticancer activity study of A3 adenosine receptor agonists
Carpanese et al. Interactomic exploration of LRRC8A in volume-regulated anion channels
Ko et al. Inhibition of chloride intracellular channel protein 1 (CLIC1) ameliorates liver fibrosis phenotype by activating the Ca2+-dependent Nrf2 pathway
EP3687559A2 (en) Compositions that target tumor-associated macrophages and methods of use therefor
Baumann Nonclinical development of biopharmaceuticals
AU2020278977B2 (en) GPCR heteromer inhibitors and uses thereof
Feng et al. In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein
Irmer et al. Syntenin Controls Extracellular Vesicle‐Induced Tumour Migration by Regulating the Expression of Adhesion Proteins on Small Extracellular Vesicles
Verma et al. Analysis of dynamic tyrosine phosphoproteome in LFA‐1 triggered migrating t‐cells
Brunetti et al. Molecular definition of the interaction between a tumor-specific tetrabranched peptide and LRP6 receptor
Foy et al. Recent advances in the characterisation of the platelet membrane system by proteomics
Rui et al. Sigma receptors as new target for multiple sclerosis
WO2005119261A2 (en) Glut5 transporters expressed in cancer cells
Haratani et al. Cancers modulate p53 truncal neoantigen display to evade T cell detection

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170725